Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-cash Items (2017 - 2022)

Historic Non-cash Items for Ani Pharmaceuticals (ANIP) over the last 7 years, with Q4 2022 value amounting to $686000.0.

  • Ani Pharmaceuticals' Non-cash Items fell 8989.1% to $686000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $686000.0, marking a year-over-year decrease of 8989.1%. This contributed to the annual value of $686000.0 for FY2022, which is 8989.1% down from last year.
  • As of Q4 2022, Ani Pharmaceuticals' Non-cash Items stood at $686000.0, which was down 8989.1% from $6.8 million recorded in Q4 2021.
  • Ani Pharmaceuticals' Non-cash Items' 5-year high stood at $6.8 million during Q4 2021, with a 5-year trough of $372000.0 in Q4 2020.
  • Its 5-year average for Non-cash Items is $3.4 million, with a median of $2.2 million in 2018.
  • Its Non-cash Items has fluctuated over the past 5 years, first crashed by 9449.79% in 2020, then surged by 172419.35% in 2021.
  • Ani Pharmaceuticals' Non-cash Items (Quarter) stood at $2.2 million in 2018, then skyrocketed by 204.41% to $6.8 million in 2019, then plummeted by 94.5% to $372000.0 in 2020, then surged by 1724.19% to $6.8 million in 2021, then tumbled by 89.89% to $686000.0 in 2022.
  • Its last three reported values are $686000.0 in Q4 2022, $6.8 million for Q4 2021, and $372000.0 during Q4 2020.